Anlon Healthcare Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹86 - ₹91
- Lot size
- 164 shares
- Issue amount
- ₹121.03 cr
- Total subscription
- 7.13×
- Opens
- 26 Aug 2025
- Closes
- 29 Aug 2025
- Allotment
- 1 Sept 2025
- Listing
- 3 Sept 2025
Offer at a glance
Issue overview
- Issue size
- 1,33,00,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹14,104
- Fresh issue
- ₹121.03 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Ltd.
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,924
- Issue type
- Bookbuilding IPO
- Shares before issue
- 3,98,51,500
- Shares after issue
- 5,31,51,500
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 164 | ₹14,924 |
| sHNI | 14 | 2,296 | ₹2,08,936 |
| bHNI | 68 | 11,152 | ₹10,14,832 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 8,110 | 3,34,697 |
| HNIs(10L +) | 579 | 878 |
| HNIs (2-10L) | 290 | 4,628 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 90.77 | 97.27 |
| RETAIL | 12.1 | 572.5 |
| HNIs 2+ | 6.05 | 101.02 |
| HNIs 10+ | 12.1 | 91.55 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 6.38 | 6.68 | 4.85 |
| ROE | 0 | 0 | 0 |
| ROCE | 21.93 | 16.29 | 17.16 |
| RONW | 25.51 | 45.92 | 78.92 |
| PRE IPO(PE) | 17.67 | 0 | 0 |
| POST IPO(PE) | 23.57 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Anlon Healthcare limited | NA | NA | 10.00 | NA | 25.51 | 6.37 |
| Kronox Lab Sciences Limited | 26.18 | 180.90 | 10.00 | 24.28 | 28.26 | 6.91 |
| AMI Organics Limited | 58.18 | 1,158.35 | 5.00 | 320.41 | 12.61 | 19.91 |
| Supriya Lifescience Limited | 29.27 | 683.35 | 2 | 18.13 | 188.57 | 23.35 |
Company information
Company profile
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in the production of pharma intermediates and active pharmaceutical ingredients (APIs). It manufactures high-purity pharmaceutical intermediates used in API production and APIs that are utilized in medicines, nutraceuticals, personal care, and animal health products. The company’s offerings are produced in compliance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP. Along with manufacturing APIs and intermediates to global standards, Anlon Healthcare also provides custom manufacturing for complex chemicals, focusing on exceeding purity standards and minimizing impurities to meet customer-specific requirements. The company has obtained Drug Master File (DMF) approval from regulatory authorities including ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. It has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. Its portfolio comprises 65 commercialized products, 28 at the pilot stage, and 49 undergoing laboratory testing. To ensure consistent product quality, the company follows rigorous testing and process improvements, supported by four laboratories and a 34-member technical team, which includes 24 science graduates. The company’s product range includes pharmaceutical intermediates such as Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine, which serve as key starting materials or advanced intermediates for API manufacturing. Its APIs are essential components in pharmaceutical products, delivering therapeutic effects and being used in various formulations like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. As of January 31, 2025, Anlon Healthcare employed 105 people (excluding trainees) along with 8 contract workers.
Strengths
- Experienced Leadership: strong promoters and skilled management driving strategy, innovation, and customer-focused growth
- High Market Barriers: strict approval cycles and standards create entry barriers, ensuring demand and limiting competition
- Advanced Quality Control: four in-house testing labs ensure rigorous checks, optimized processes, and compliance
Risk factors
- Strict Quality Compliance Risk: not meeting specifications or audits may cause cancellations, claims, or business loss
- Customer Dependence: limited client base, loss of a key customer can impact revenue and cash flow
- Pharma Industry Reliance: heavy dependence on pharma demand, decline or new alternatives may hurt growth and profitability
Promoters
Punitkumar R. rasadia
Meet Atulkumar Vachhani
Mamata punitkumar Rasadia
Registrar & documents
Lead manager
Interactive Financial Services Limited
Registrar & contacts
Kfin Technologies Ltd.
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005
+91 281 2562538
[email protected]Company website ↗Understanding AHCL IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.